97. Ulcerative colitis
2,269 clinical trials,   1,331 drugs   (DrugBank: 241 drugs),   114 drug target genes,   181 drug target pathways

Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04272307
(ClinicalTrials.gov)
May 14, 202014/2/2020MIcroorganisms as Triggers in Acute Severe Ulcerative Colitis and Their Influence on Medical Therapy Efficacy: a Multi-omics Pilot Approach.MIcroorganisms as Triggers in Acute Severe Ulcerative Colitis and Their Influence on Medical Therapy Efficacy: a Multi-omics Pilot Approach.Inflammatory Bowel Diseases;Colitis;UlcerativeBiological: Blood samples;Procedure: Stool samples;Procedure: Colorectal biopsiesUniversity Hospital, BordeauxMcGill University Health Centre/Research Institute of the McGill University Health CentreRecruiting18 YearsN/AAll40France
2NCT04030676
(ClinicalTrials.gov)
July 17, 201919/7/2019QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative ColitisPlace of the QuantiFERON-CMV (QF-CMV) Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis (UC)Cytomegalovirus InfectionsProcedure: Biopsies;Biological: Blood samplesCentre Hospitalier Universitaire de Saint EtienneNULLRecruiting18 YearsN/AAll196N/AFrance
3NCT03182166
(ClinicalTrials.gov)
November 21, 201729/5/2017Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose OptimizationPharmacokinetic and Pharmacodynamic Study of Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose OptimizationUlcerative ColitisDrug: Golimumab (Optimization);Diagnostic Test: Rectosigmoidoscopy;Biological: Blood samplesCentre Hospitalier Universitaire de Saint EtienneMerck Sharp & Dohme Corp.Recruiting18 YearsN/AAll80Phase 2France